An unanticipated severe neurologic disorder occurred after ingestion of BIA 10-2474 at the highest dose level used in a phase 1 trial,” said the NEJM report. “The underlying mechanism of this toxic cerebral syndrome remains unknown.”Neurology Today16 45 (2016)
In January 2016 an experimental study on a fatty acid amide hydrolase inhibitor of the type FIH, led to death of a healthy volunteer[1] A case of cummulative toxicity [2]
The molecule from Bial pharmaceutical company (Portela ca, Portugal) intended for enhancement of anandamide levels, its has a licking score (a formalin paw test) comparable to reference molecule gabapentine 300mg and 10 mg /Kg has a tail flick test maximum at 8 hour
Links[]
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase